Figure 3From: Efficacy of plasma vascular endothelial growth factor in monitoring first-line chemotherapy in patients with advanced non-small cell lung cancer Receiver-operating characteristics (ROC) curves for an early estimation of response to therapy by plasma VEGF levels available before the start of therapy cycle 1 (BV1), cycle 2 (BV2), and cycle 3 (BV3).Back to article page